Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics nets $297.0 million in stock sale and $250.8 million in notes

Neutral Impact 4 of 5 financing Written later

Viking Therapeutics sold 7,857,143 shares of common stock at $35.00 per share and separately sold $225.0 million of 2.00% convertible senior notes due 2032, with underwriters exercising their options in full. Net proceeds were about $297.0 million from the stock sale and about $250.8 million from the notes, which the company intends to use for its VK2735 and VK3019 programs and general corporate purposes. The stock sale adds shares outstanding for existing shareholders, and the notes add debt that could convert into common stock at about $50.75 per share.

Key points

  • Stock: 7,857,143 shares at $35.00 per share, plus 1,178,571 option shares exercised in full on September 24, 2026; closed September 25, 2026; net proceeds about $297.0 million
  • Notes: $225.0 million of 2.00% convertible senior notes due October 15, 2032, plus a $33,750,000 option exercised in full on September 24, 2026; net proceeds about $250.8 million
  • Conversion price about $50.75 per share (19.7044 shares per $1,000 principal); company may settle conversions in cash, shares or a combination
  • Proceeds intended for VK2735 and VK3019 clinical programs and general corporate purposes

The filing

CompanyViking Therapeutics, Inc. (VKTX)
Form8-K, current report
Filed with the SECSep 28, 2026, 5:27 PM ET
Accession number0001193125-26-405580

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.